Breaking News, Collaborations & Alliances

Isis Earns GSK Milestone

Advances ISIS-TTR in FAP

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $2 million milestone payment from GlaxoSmithKline for the advancement of an ongoing Phase II/III study of ISIS-TTR in patients with familial amyloid polyneuropathy (FAP), a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.   The Phase II/III study is a randomized, double-blind, placebo-controlled, study will support an application for marketing approval of ISIS-TTR in patients with FAP. The s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters